Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $39,776.10 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Trading Down 2.6 %

Shares of NASDAQ:TWST opened at $52.30 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.54 and a current ratio of 4.96. The firm has a fifty day moving average price of $48.84 and a 200 day moving average price of $46.32. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The business’s revenue was up 24.1% on a year-over-year basis. On average, equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TWST. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners lifted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Scotiabank upped their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.80.

Institutional Trading of Twist Bioscience

Large investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $209,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Twist Bioscience by 5.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,064 shares of the company’s stock worth $793,000 after buying an additional 821 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of Twist Bioscience by 216.9% in the 4th quarter. AlphaQuest LLC now owns 11,422 shares of the company’s stock worth $531,000 after buying an additional 7,818 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in shares of Twist Bioscience by 64.1% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 102,928 shares of the company’s stock valued at $4,497,000 after buying an additional 40,189 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Twist Bioscience in the 4th quarter valued at about $2,224,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.